Loading...
•
Sep 30
Arcutis Q3 2025 Earnings Report
Arcutis reported its financial results for the third quarter of 2025, highlighting significant revenue growth for ZORYVE and strategic initiatives for future expansion.
Key Takeaways
Arcutis Biotherapeutics achieved strong financial performance in Q3 2025, with net product revenue reaching $99.2 million, a 122% increase year-over-year. The company reported a net income of $7.4 million, a significant turnaround from a loss in the prior year, driven by increased ZORYVE sales and strategic commercialization efforts.
Net product revenue for ZORYVE was $99.2 million, marking a 122% increase compared to Q3 2024.
The company achieved a net income of $7.4 million, or $0.06 per basic and diluted share, compared to a net loss in the prior year.
ZORYVE cream 0.05% received FDA approval for atopic dermatitis in children down to 2 years of age, expanding its market reach.
Arcutis provided initial 2026 full-year net product sales guidance of $455–$470 million, indicating strong future growth expectations.
Arcutis
Arcutis
Arcutis Revenue by Segment
Revenue by Segment
ZORYVE cream 0.3% Revenue
CapyFin.comZORYVE cream 0.15% Revenue
CapyFin.comZORYVE topical foam 0.3% Revenue
CapyFin.com Forward Guidance
Arcutis anticipates strong net product revenue for the full year 2026, driven by continued ZORYVE franchise growth, expansion into new markets, and advancement of its clinical pipeline.
Positive Outlook
- Initial 2026 full-year net product sales guidance of $455–$470 million.
- Continued conversion of the topical corticosteroid market for the ZORYVE franchise.
- Expansion of ZORYVE into new markets through potential additional indications, starting with Phase 2 trials in vitiligo and hidradenitis suppurativa.
- Advancement of the clinical pipeline with ARQ-234 and potential external innovation.
- Potential peak ZORYVE sales of $2.6–$3.5 billion per annum across current and future indications.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The company acknowledges inherent risks in clinical development and regulatory approval processes.
- Uncertainty of future commercial sales and related items that can impact net sales.
- Challenges in defending intellectual property.
- Reliance on the success of the ZORYVE franchise for sustained growth.